Comparable Efficacy Between Ongoing Versus Initiation of Antiviral Therapy at Treatment for HBV-related Hepatocellular Carcinoma.

Authors
Category Primary study
JournalClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Year 2022
Suppression of hepatitis B virus (HBV) replication with antiviral therapy (AVT) using nucleos(t)ide analogs reduces the risk of hepatocellular carcinoma (HCC) recurrence and prolongs survival after curative treatment.[1-5] Studies of the association between timing of AVT initiation and prognosis of patients with HCC receiving curative treatment are scarce. In the present study, we compared the therapeutic benefit of AVT, commenced before vs after curative treatment of HBV-related HCC, on long-term prognosis.
Epistemonikos ID: 7ffc7c672a4cc12211d1c21dc0f3353ea2bff6dc
First added on: Nov 08, 2024